0
0
A recent landmark clinical trial published in JAMA Internal Medicine has brought to light promising evidence that a widely available over-the-counter nasal spray, azelastine, commonly used to treat seasonal allergies, may significantly reduce the risk of Covid-19 infection. Conducted by researchers at Saarland University Hospital in Germany from March 2023 to July 2024, this phase 2 randomized, double-blind, placebo-controlled trial involved 450 healthy adults aged 18 to 65. The study showed that those who used azelastine nasal spray three times daily had a Covid infection rate of 2.2%, a striking 67% reduction compared with the 6.7% infection rate seen in the placebo group.
Key Findings
The trial divided participants into two groups: 227 subjects received azelastine nasal spray, and 223 were given a placebo, both instructed to spray each nostril three times daily for 56 days. Covid-19 rapid antigen tests were administered twice weekly, with PCR confirmation for positives. Beyond the primary finding of a significant reduction in confirmed Covid infections, the azelastine group also experienced fewer symptomatic respiratory infections, including rhinovirus, suggesting broader antiviral protection.
Lead investigator Dr. Robert Bals, a professor of internal and pulmonary medicine, commented that the spray’s protective benefit may stem from its ability to bind the virus in the nasal mucosa or interfere with viral entry pathways via the ACE2 receptor—the key cellular gateway for SARS-CoV-2. While the exact mechanism remains under study, these results mark an important step toward scalable, non-invasive prophylactic options to complement vaccines and masks, especially in high-risk settings such as crowded indoor gatherings or travel.
Expert Perspectives and Context
Independent experts find these findings encouraging but urge caution. Dr. William Messer, professor of microbiology and immunology at Oregon Health & Science University, described the study as “reasonably convincing” for risk reduction but noted challenges regarding adherence to a thrice-daily nasal spray regimen compared to more convenient preventive approaches, such as mask-wearing. He highlighted the importance of continued research in diverse populations, particularly older adults and immunocompromised individuals, who bear the greatest burden of serious Covid complications.
This trial emerges amid ongoing Covid waves and waning vaccine coverage in many populations, underscoring the potential value of an adjunctive protective tool. Unlike vaccines, azelastine has a long history of safe, over-the-counter use for allergic rhinitis, making it readily accessible. The spray’s safety profile was confirmed in the study, with only two serious adverse events reported, neither deemed related to treatment.
Public Health Implications
If further large-scale, multicenter trials corroborate these findings, azelastine nasal spray could become an important, affordable, and easy-to-use prophylactic option to supplement existing Covid defenses. It may help fill protection gaps in unvaccinated or high-exposure groups during times of viral surges or for transient high-risk activities like air travel and mass gatherings.
Health officials could consider incorporating nasal spray prophylaxis as part of integrated Covid prevention strategies. However, experts emphasize it should never replace vaccination, the cornerstone of Covid-19 control, but rather act as an additional layer—akin to hand hygiene and masking.
Limitations and Next Steps
The trial’s limitations include its relatively young, healthy participant population, restricting generalizability to more vulnerable groups. Also, the study lasted less than two months, and longer-term efficacy and safety data are needed. The precise antiviral mechanisms require further elucidation through molecular research.
Additional randomized controlled trials are needed to confirm efficacy across diverse demographics and settings, optimize dosing frequency, and explore potential benefits against other respiratory pathogens such as influenza and respiratory syncytial virus (RSV).
Practical Takeaway for Readers
For health-conscious individuals, azelastine nasal spray represents a promising supplementary tool to reduce Covid risk, especially when combined with vaccination, masking, and other recommended public health measures. Its ease of use and OTC availability make it particularly appealing for short-term protection during spikes in viral transmission or before travel.
In summary, this new evidence highlights an accessible nasal spray with antiviral potential that can strengthen community defenses against Covid-19, pending further validation.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
